October 2025 – Page 3

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

2 months ago talkbio0Tagged Drug Development, Generic competition, impairment charges, Late stage, Operating, pipeline, Q2 sales, restructuring, Takeda, Vyvanse

Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

2 months ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

2 months ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

2 months ago talkbio0Tagged Amsterdam facility, Awards, cell analysis, Collaboration, Cytek Biosciences, European (ethnic group), expansion, Flow Cytometry, FSP, Instrument - device, ISAC, Research Projects, R-Series, Spectrum Profiling

Cytek Biosciences; flow cytometry; access expansion; ISAC collaboration; instrument awards; research grants; Full Spectrum Profiling (FSP); European expansion; Amsterdam facility; cell analysis

United Imaging Healthcare Q3 2025 Results: Overseas Revenue Up 42% YoY

2 months ago talkbio0Tagged Global Expansion, Investments, Market, Medical Imaging, overseas, Q3, revenue growth, United Imaging Healthcare

United Imaging Healthcare; Q3 2025 results; overseas revenue growth; medical imaging; emerging markets; R&D investment; global expansion

Vistagen Appoints Paul Edick to its Board of Directors

2 months ago talkbio0Tagged Audit Committee, Biological Factors, board of directors, Compensation Committee, Corporate governance, Drug Industry, Paul Edick, Vistagen

Vistagen; Paul Edick; Board of Directors; Audit Committee; Compensation Committee; Biopharmaceutical; Pharmaceutical industry; Corporate governance

Astellas Pharma Revises Financial Forecasts for FY2025

2 months ago talkbio0Tagged Astellas, Drug Industry, Financial Forecast Revision, FY2025, operating profit, Optimization, Pipeline Progress, Revenue Upgrade, SG&A, strategic brands

Astellas; Financial Forecast Revision; FY2025; Revenue Upgrade; Operating Profit; Pharmaceutical Industry; Strategic Brands; Pipeline Progress; SG&A Optimization

GSK Trims Pipeline and Upgrades Guidance in Emma Walmsley’s Last Earnings Report

2 months ago talkbio0Tagged dividend, earnings, Emma Walmsley, guidance upgrade, Medical Specialities, operating profit, pipeline reduction, R&D, SmithKline Beecham

GSK; pipeline reduction; earnings; Emma Walmsley; Q3 2025; guidance upgrade; Specialty Medicines; operating profit; dividend; R&D progress

BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus

2 months ago talkbio0Tagged BioMarin, Divestment, gene therapy, Hemophilia A, out-licensing, portfolio strategy, Roctavian

BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge

Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery

2 months ago talkbio0Tagged Artificial Intelligence, biomedical foundation models, Blackwell Ultra GPU, Clinical Trials, Drug Discovery, Drug Industry, eli lilly, high-performance computing, NVIDIA, supercomputer

Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing